newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra
Health

Alembic Pharmaceuticals announces USFDA Final Approval for Betamethasone Valerate Foam, 0.12%

Alembic Pharmaceuticals announces USFDA Final Approval for Betamethasone Valerate Foam, 0.12%

27 August 2024, Bengaluru: Alembic Pharmaceuticals Limited (Alembic) announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Betamethasone Valerate Foam, 0.12%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Luxiq Foam, 0.12%, of Norvium Bioscience, LLC (Norvium).

Betamethasone valerate foam, 0.12% is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. Refer label for a detailed indication.

Alembic has a cumulative total of 213 ANDA approvals (185 final approvals and 28 tentative approvals) from USFDA.

Related posts

Mithapur Hospital and GG Medical Hospital organise a Blood Donation Camp  

Newsmantra

IHH Healthcare Redefines Healthcare Leadership Through Focus on Quality and Innovation

Newsmantra

World Heart Day: Understanding the Different Heart Health Specialists You May Need to See

Newsmantra

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More